CN109851610B - 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物 - Google Patents

作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物 Download PDF

Info

Publication number
CN109851610B
CN109851610B CN201910003375.6A CN201910003375A CN109851610B CN 109851610 B CN109851610 B CN 109851610B CN 201910003375 A CN201910003375 A CN 201910003375A CN 109851610 B CN109851610 B CN 109851610B
Authority
CN
China
Prior art keywords
octane
piperidin
azaspiro
carboxylate
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910003375.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109851610A (zh
Inventor
盖尔斯·艾伯特·布朗
朱莉·伊莱恩·坎斯菲尔德
迈尔斯·斯图尔特·康格里夫
迈克尔·阿里斯代尔·奥布莱恩
马克·皮克沃斯
马克·大卫·雷克汉姆
本杰明·杰拉尔德·特汉
巴里·约翰·泰奥博尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52465550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109851610(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of CN109851610A publication Critical patent/CN109851610A/zh
Application granted granted Critical
Publication of CN109851610B publication Critical patent/CN109851610B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CN201910003375.6A 2014-02-06 2015-02-06 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物 Active CN109851610B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GB1402013.5 2014-02-06
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds
GB1416622.7 2014-09-19
CN201580017993.6A CN106458986B (zh) 2014-02-06 2015-02-06 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580017993.6A Division CN106458986B (zh) 2014-02-06 2015-02-06 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物

Publications (2)

Publication Number Publication Date
CN109851610A CN109851610A (zh) 2019-06-07
CN109851610B true CN109851610B (zh) 2021-09-21

Family

ID=52465550

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910003375.6A Active CN109851610B (zh) 2014-02-06 2015-02-06 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物
CN201580017993.6A Active CN106458986B (zh) 2014-02-06 2015-02-06 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580017993.6A Active CN106458986B (zh) 2014-02-06 2015-02-06 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物

Country Status (30)

Country Link
US (6) US9670183B2 (enExample)
EP (4) EP3102568B1 (enExample)
JP (7) JP6479029B2 (enExample)
KR (1) KR102352388B1 (enExample)
CN (2) CN109851610B (enExample)
AU (3) AU2015213900B2 (enExample)
BR (1) BR112016017979B1 (enExample)
CA (1) CA2938169C (enExample)
CL (1) CL2016001983A1 (enExample)
CY (1) CY1120834T1 (enExample)
DK (2) DK3406609T3 (enExample)
ES (2) ES2688548T3 (enExample)
FI (1) FI3406609T3 (enExample)
HR (2) HRP20181499T1 (enExample)
HU (1) HUE068301T2 (enExample)
IL (1) IL247117B (enExample)
LT (2) LT3406609T (enExample)
MX (2) MX371529B (enExample)
NZ (1) NZ723103A (enExample)
PH (1) PH12016501570A1 (enExample)
PL (2) PL3102568T3 (enExample)
PT (2) PT3406609T (enExample)
RS (2) RS57843B1 (enExample)
RU (1) RU2685230C2 (enExample)
SA (1) SA516371614B1 (enExample)
SG (1) SG11201606269WA (enExample)
SI (2) SI3102568T1 (enExample)
SM (1) SMT202400446T1 (enExample)
UA (1) UA122121C2 (enExample)
WO (1) WO2015118342A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
WO2014145986A1 (en) 2013-03-15 2014-09-18 Verseon, Inc. Multisubstituted aromatic compounds as serine protease inhibitors
EP3102568B1 (en) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201404922D0 (en) * 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
HUE054857T2 (hu) * 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3643703A4 (en) 2017-06-21 2020-12-23 Daiichi Sankyo Co., Ltd. EP300 / CREBBP INHIBITOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
ES3064093T3 (en) 2017-10-20 2026-04-22 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20221454A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
CN114555592B (zh) * 2019-10-09 2024-09-06 诺华股份有限公司 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物
TW202134231A (zh) 2019-12-06 2021-09-16 美商紐羅克里生物科學有限公司 蕈毒受體4拮抗劑及使用方法
JP7707176B2 (ja) * 2020-02-05 2025-07-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド ムスカリン性受容体４アンタゴニストおよび使用方法
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
TW202416955A (zh) 2022-08-04 2024-05-01 英商海普泰爾思治療公司 毒蕈鹼受體激動劑
EP4587432A1 (en) * 2022-09-16 2025-07-23 Cerevel Therapeutics, LLC M4 activators/modulators and uses thereof
AU2024208125A1 (en) * 2023-01-12 2025-07-10 Cerevel Therapeutics, Llc Spiro derivatives as m4 activators/modulators and uses thereof
WO2024158645A1 (en) * 2023-01-24 2024-08-02 Neurocrine Biosciences, Inc. Deuterated compounds
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法
CN121605195A (zh) 2023-08-03 2026-03-03 纽罗克里生物科学有限公司 合成方法
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
WO2026050225A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a neurological or psychiatric disease or disorder
WO2026050278A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist
WO2026050229A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a neurological or psychiatric disease or disorder
WO2026050238A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder
WO2026050231A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a bipolar disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119716A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
CN101395148A (zh) * 2006-03-03 2009-03-25 诺瓦提斯公司 N-甲酰基羟胺化合物
WO2012020813A1 (ja) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
WO2013072705A1 (en) * 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
CA2568524A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
JP2009521483A (ja) 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1987034B1 (en) * 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
DK2897948T3 (en) * 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
US9505745B2 (en) 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
MA39317A1 (fr) 2014-02-06 2018-01-31 Riboscience Llc Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
EP3102568B1 (en) * 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
KR102209667B1 (ko) 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
MX2017003664A (es) 2014-09-19 2017-07-13 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1.
BR112017005660A2 (pt) 2014-09-19 2017-12-19 Glaxosmithkline Ip Dev Ltd novos ativadores de guanilato ciclase solúvel e sua utilização

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101395148A (zh) * 2006-03-03 2009-03-25 诺瓦提斯公司 N-甲酰基羟胺化合物
WO2008119716A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2012020813A1 (ja) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
WO2013072705A1 (en) * 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists

Also Published As

Publication number Publication date
BR112016017979B1 (pt) 2022-08-02
AU2020277225A1 (en) 2020-12-24
CL2016001983A1 (es) 2017-06-23
AU2015213900A1 (en) 2016-08-11
PH12016501570B1 (en) 2016-10-03
JP2019077725A (ja) 2019-05-23
EP3406609A1 (en) 2018-11-28
IL247117A0 (en) 2016-09-29
JP2017505323A (ja) 2017-02-16
HK1231473A1 (en) 2017-12-22
US10196380B2 (en) 2019-02-05
MX371529B (es) 2020-01-31
LT3102568T (lt) 2018-11-12
PH12016501570A1 (en) 2016-10-03
RS57843B1 (sr) 2018-12-31
US20200325118A1 (en) 2020-10-15
EP4413985A2 (en) 2024-08-14
EP3102568A1 (en) 2016-12-14
JP7652833B2 (ja) 2025-03-27
SMT202400446T1 (it) 2024-11-15
AU2019201579A1 (en) 2019-03-28
RU2016133684A (ru) 2018-03-14
US10961225B2 (en) 2021-03-30
US20170240530A1 (en) 2017-08-24
US10385039B2 (en) 2019-08-20
SI3406609T1 (sl) 2024-10-30
ES2688548T3 (es) 2018-11-05
CN106458986A (zh) 2017-02-22
US20190337925A1 (en) 2019-11-07
WO2015118342A1 (en) 2015-08-13
LT3406609T (lt) 2024-09-25
KR102352388B1 (ko) 2022-01-17
EP4413985A3 (en) 2024-10-23
KR20160129014A (ko) 2016-11-08
DK3102568T3 (en) 2018-10-08
PT3102568T (pt) 2018-10-24
ES2986327T3 (es) 2024-11-11
SI3102568T1 (sl) 2018-11-30
RU2685230C2 (ru) 2019-04-17
AU2019201579B2 (en) 2020-08-27
MX393637B (es) 2025-03-11
CA2938169A1 (en) 2015-08-13
JP2023087045A (ja) 2023-06-22
CN109851610A (zh) 2019-06-07
RS65894B1 (sr) 2024-09-30
JP2025085736A (ja) 2025-06-05
JP7652832B2 (ja) 2025-03-27
US20180179184A1 (en) 2018-06-28
PT3406609T (pt) 2024-09-17
EP4714446A2 (en) 2026-03-25
MX2016010322A (es) 2017-04-27
EP3406609B1 (en) 2024-06-26
HRP20181499T1 (hr) 2018-11-30
US20170015650A1 (en) 2017-01-19
AU2015213900B2 (en) 2018-12-13
US9670183B2 (en) 2017-06-06
CN106458986B (zh) 2019-01-04
US9926297B2 (en) 2018-03-27
RU2016133684A3 (enExample) 2018-08-31
FI3406609T3 (fi) 2024-09-10
CA2938169C (en) 2022-03-15
JP6479029B2 (ja) 2019-03-06
EP3102568B1 (en) 2018-06-27
WO2015118342A8 (en) 2016-06-30
BR112016017979A2 (enExample) 2017-08-08
US10689368B2 (en) 2020-06-23
US20190112294A1 (en) 2019-04-18
DK3406609T3 (da) 2024-08-26
HUE068301T2 (hu) 2024-12-28
IL247117B (en) 2021-03-25
UA122121C2 (uk) 2020-09-25
JP2021006571A (ja) 2021-01-21
JP6774513B2 (ja) 2020-10-28
SA516371614B1 (ar) 2019-10-30
PL3102568T3 (pl) 2019-01-31
JP2023073504A (ja) 2023-05-25
NZ723103A (en) 2022-09-30
MX2020001236A (es) 2022-06-30
EP4413985B1 (en) 2026-05-06
JP7652829B2 (ja) 2025-03-27
CY1120834T1 (el) 2019-12-11
SG11201606269WA (en) 2016-09-29
HRP20241145T1 (hr) 2024-11-22
JP2023087046A (ja) 2023-06-22
PL3406609T3 (pl) 2024-11-25

Similar Documents

Publication Publication Date Title
JP7652833B2 (ja) ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
HK40007500A (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
RU2811601C1 (ru) Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
RU2811601C9 (ru) Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
HK40007500B (zh) 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物
HK40114593A (en) Pharmaceutical compounds
HK1231473B (en) Bicyclic aza compounds as muscarinic m1 receptor agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: England

Applicant after: Heptares Therapeutics Ltd.

Address before: Hertfordshire

Applicant before: Heptares Therapeutics Ltd.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007500

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: cambridge

Patentee after: Nexla Pharmaceuticals UK Ltd.

Country or region after: United Kingdom

Address before: cambridge

Patentee before: Heptares Therapeutics Ltd.

Country or region before: United Kingdom

CP03 Change of name, title or address